Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 26;14(12):2612.
doi: 10.3390/pharmaceutics14122612.

Photodynamic Opening of the Blood-Brain Barrier and the Meningeal Lymphatic System: The New Niche in Immunotherapy for Brain Tumors

Affiliations
Review

Photodynamic Opening of the Blood-Brain Barrier and the Meningeal Lymphatic System: The New Niche in Immunotherapy for Brain Tumors

Oxana Semyachkina-Glushkovskaya et al. Pharmaceutics. .

Abstract

Photodynamic therapy (PDT) is a promising add-on therapy to the current standard of care for patients with glioblastoma (GBM). The traditional explanation of the anti-cancer PDT effects involves the PDT-induced generation of a singlet oxygen in the GBM cells, which causes tumor cell death and microvasculature collapse. Recently, new vascular mechanisms of PDT associated with opening of the blood-brain barrier (OBBB) and the activation of functions of the meningeal lymphatic vessels have been discovered. In this review, we highlight the emerging trends and future promises of immunotherapy for brain tumors and discuss PDT-OBBB as a new niche and an important informative platform for the development of innovative pharmacological strategies for the modulation of brain tumor immunity and the improvement of immunotherapy for GBM.

Keywords: blood-brain barrier; glioblastoma; immunotherapy for brain tumors; meningeal lymphatic vessels; photodynamic therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interest.

Figures

Figure 1
Figure 1
Schematic illustration of intracavitary PDT and interstitial PDT for GBM with an energy diagram of the oxygen response after PS excitation by an appropriate light wavelength. In the singlet state, energy is converted to heat by internal conversion or emitted as fluorescence. Then, PS in the excited singlet state can convert to the excited triplet state. In the triplet state, the energy can undergo a Type 1 or Type 2 redox reaction with the generation of the reactive oxygen species (ROS), which induces the death of the GBM cells via necrosis and/or apoptosis. This can also destruct the GBM vasculature and produce an acute inflammatory response that attracts leukocyte activation.
Figure 2
Figure 2
The lymphatic clearance of tracer from the brain after crossing the OBBB. The figure illustrates the fluorescent microscopy of the clearance of TRITC-dextran 70 kDa (red color) from the brain via the meningeal lymphatics (green color, labelled by the specific antibodies LYVE-1 conjugated with Alexa 488). The intravenously injected TRITC-dextran is immediately observed in the Sagittal sinus (the main cerebral vein), and 30 min later, it is also present in the meningeal lymphatics due to the PDT-OBBB-mediated activation of the lymphatic clearance of tracer from the brain [43].
Figure 3
Figure 3
Schematic illustration of the depth of the penetration of light into the head and brain tissues, depending on the wavelength.
Figure 4
Figure 4
PDT-OBBB modulation of brain tumor immunity. The cancer immunity cycle in GBM involves the APC release and lymphatic traffic of APCs into the dCLNs (1), where they activate CD4+/CD8+-T cells (2). The T-cells migrate from the dcLNs to the GBM, extravasate into the tumor tissues via OBBB (3), and, finally, the T cells induce GBM cytotoxicity, releasing more GBM antigens and contributing to brain tumor immunity.

Similar articles

Cited by

References

    1. Mitusova K., Peltek O.O., Karpov T.E., Muslimov A.R., Zyuzin M.V., Timin A.S. Overcoming the blood–brain barrier for the therapy of malignant brain tumor: Current status and prospects of drug delivery approaches. J. Nanobiotechnol. 2022;20:412–463. doi: 10.1186/s12951-022-01610-7. - DOI - PMC - PubMed
    1. Brain, Central Nervous System. [(accessed on 11 April 2022)]. Available online: https://gco.iarc.fr/today.
    1. Ostrom Q.T., Cioffi G., Gittleman H., Patil N., Waite K., Kruchko C., Barnholtz-Sloan J.S. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2012–2016. Neuro. Oncol. 2019;21:v1–v100. doi: 10.1093/neuonc/noz150. - DOI - PMC - PubMed
    1. Ostrom Q.T., Cote D.J., Ascha M., Kruchko C., Barnholtz-Sloan J.S. Adult glioma incidence and survival by race or ethnicity in the United States from 2000 to 2014. JAMA Oncol. 2018;4:1254–1262. doi: 10.1001/jamaoncol.2018.1789. - DOI - PMC - PubMed
    1. Minniti G., Lombardi G., Paolini S. Glioblastoma in elderly patients: Current management and future perspectives. Cancers. 2019;11:336. doi: 10.3390/cancers11030336. - DOI - PMC - PubMed

LinkOut - more resources